Millennium Management LLC Has $171,000 Stock Holdings in Codexis, Inc. (NASDAQ:CDXS)

Millennium Management LLC reduced its stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) by 97.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,931 shares of the biotechnology company's stock after selling 1,364,128 shares during the quarter. Millennium Management LLC's holdings in Codexis were worth $171,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CDXS. Summit Investment Advisors Inc. lifted its position in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 3,783 shares in the last quarter. Fiduciary Trust Co bought a new stake in Codexis in the 4th quarter valued at $65,000. Group One Trading LLC bought a new stake in Codexis in the 4th quarter valued at $73,000. Price T Rowe Associates Inc. MD lifted its position in Codexis by 38.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 31,552 shares of the biotechnology company's stock valued at $151,000 after acquiring an additional 8,832 shares in the last quarter. Finally, Intech Investment Management LLC lifted its position in Codexis by 55.1% in the 4th quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 11,757 shares in the last quarter. 78.54% of the stock is owned by institutional investors.

Codexis Stock Up 0.4%

NASDAQ:CDXS traded up $0.01 on Monday, hitting $2.24. 512,980 shares of the company's stock were exchanged, compared to its average volume of 713,636. The firm has a 50-day moving average price of $2.34 and a 200-day moving average price of $3.48. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis, Inc. has a 52 week low of $1.90 and a 52 week high of $6.08. The company has a market cap of $185.57 million, a P/E ratio of -2.57 and a beta of 2.52.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The business had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. As a group, analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Codexis to a "sell" rating in a research report on Friday, May 16th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.